Evidence map›Paper›PMID 33716290›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Impact of Annual Cardiovascular Screening Tests in Patients with Type 2 Diabetes Mellitus without Previous Histories of Cardiovascular Disease: Four-year Clinical Outcomes.

Yoshibumi Antoku, Masao Takemoto, Takahiro Mito, Ryuta Shiiyama, Hiroko Otsuka-Morisaki, Atsushi Tanaka, Yasutaka Maeda, Takuya Tsuchihashi

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yoshibumi AntokuCardiovascular Center, Steel Memorial Yawata Hospital, Japan.
Masao TakemotoCardiovascular Center, Steel Memorial Yawata Hospital, Japan.
Takahiro MitoDepartment of Cardiology, Munakata Suikokai General Hospital, Japan.
Ryuta ShiiyamaDepartment of Cardiology, Munakata Suikokai General Hospital, Japan.
Hiroko Otsuka-MorisakiDiabetes and Endocrine Center, Munakata Suikokai General Hospital, Japan.
Atsushi TanakaDepartment of Cardiology, Munakata Suikokai General Hospital, Japan.
Yasutaka MaedaDiabetes and Endocrine Center, Munakata Suikokai General Hospital, Japan.
Takuya TsuchihashiCardiovascular Center, Steel Memorial Yawata Hospital, Japan.
Yao Tokushukai General Hospital · JPNippon Steel Yawata Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective We previously reported that, among asymptomatic patients with type 2 diabetes mellitus (T2DM) without a history of cardiovascular disease (CVD), up to 19% of the patients with myocardial ischemia were detected by annual cardiovascular screening tests (ACVSTs). Thus, the present study assessed the long-term clinical outcomes of ACVSTs in those patients. Methods Six hundred and fifty-seven outpatients with T2DM who received ACVSTs at least once or not at all from April 2014 to March 2018 were defined as the S and NS groups, respectively. The data were compared between these two groups. Results This study revealed that, among outpatients with T2DM in our hospital over those four years, with the increasing frequency of receiving ACVSTs, 1) the frequency of the internal use of statins, anti-platelets, and renin-angiotensin system inhibitors, which are well-known as medications for preventing CVD, significantly increased; 2) low-density lipoprotein-cholesterol and triglyceride levels significantly improved; 3) levels of highly sensitive C-protein, a strong predictors of CVD, were significantly suppressed; 4) the progression of renal dysfunction was significantly suppressed; 5) the cumulative of four-point major adverse cardiovascular events and admissions due to heart failure significantly decreased; and 6) the cumulative of all-cause mortality was significantly suppressed. Conclusions Given the above, it may be important to continue ACVSTs in outpatients with T2DM without a history of CVD for several years.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial IschemiaCholesterol, LDLHumansCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitorsall-cause mortalitycardiovascular eventscardiovascular screening testcoronary artery diseasediabetes mellitusheart failure

Identifiers

PMID33716290
PMCPMC8479217
OpenAlexW3138777165

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.